Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-Flu-BLAST-PC: PSMA or Fluciclovine PET/CT Site-Directed Therapy in Oligometastatic Prostate Cancer
NCT04175431Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Sep 2020
- Primary completion
- Jul 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Abiraterone Acetate Tablets (I) in prostate adenocarcinoma (3 arms), sponsored by University of Washington. Primary endpoint: Undetectable PSA (< 0.2 ng/mL) rate at 2 years. Started Sep 2020; status: recruiting.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT04175431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04175431.